Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2021-12, Vol.5 (23), p.5107-5111
Hauptverfasser:	Tiong, Ing S., Dillon, Richard, Ivey, Adam, Kuzich, James A., Thiagarajah, Nisha, Sharplin, Kirsty M., Kok, Chung Hoow, Tedjaseputra, Aditya, Rowland, James P., Grove, Carolyn S., Abro, Emad, Shortt, Jake, Hiwase, Devendra K., Bajel, Ashish, Potter, Nicola E., Smith, Matthew L., Hemmaway, Claire J., Thomas, Abin, Gilkes, Amanda F., Russell, Nigel H., Wei, Andrew H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Hematology Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Life Sciences & Biomedicine Mutation Neoplasm, Residual Nuclear Proteins - genetics Remission Induction Science & Technology Stimulus Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level
ISSN:	2473-9529 2473-9537
DOI:	10.1182/bloodadvances.2021005455